GENT Stock Overview
Researches, develops, and produces biochemical reagents for use in medical diagnostics and research worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Gentian Diagnostics ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 56.00 |
| 52 Week High | NOK 61.00 |
| 52 Week Low | NOK 34.80 |
| Beta | 0.58 |
| 11 Month Change | 24.44% |
| 3 Month Change | 46.60% |
| 1 Year Change | 27.27% |
| 33 Year Change | -12.50% |
| 5 Year Change | 12.90% |
| Change since IPO | 115.38% |
Recent News & Updates
Investors Appear Satisfied With Gentian Diagnostics ASA's (OB:GENT) Prospects As Shares Rocket 33%
Jun 29
Analyst Estimates: Here's What Brokers Think Of Gentian Diagnostics ASA (OB:GENT) After Its Annual Report
Feb 14Recent updates
Investors Appear Satisfied With Gentian Diagnostics ASA's (OB:GENT) Prospects As Shares Rocket 33%
Jun 29Analyst Estimates: Here's What Brokers Think Of Gentian Diagnostics ASA (OB:GENT) After Its Annual Report
Feb 14Here's Why We're Not At All Concerned With Gentian Diagnostics' (OB:GENT) Cash Burn Situation
Oct 28We're Not Worried About Gentian Diagnostics' (OB:GENT) Cash Burn
May 11Can You Imagine How Gentian Diagnostics' (OB:GENT) Shareholders Feel About The 57% Share Price Increase?
Mar 20What Percentage Of Gentian Diagnostics AS (OB:GENT) Shares Do Insiders Own?
Feb 21Have Insiders Been Selling Gentian Diagnostics AS (OB:GENT) Shares?
Jan 17
Gentian Diagnostics AS (OB:GENT): When Will It Breakeven?
Dec 14Shareholder Returns
| GENT | NO Medical Equipment | NO Market | |
|---|---|---|---|
| 7D | 3.7% | 1.3% | -0.4% |
| 1Y | 27.3% | 8.6% | 8.3% |
Return vs Industry: GENT exceeded the Norwegian Medical Equipment industry which returned 9% over the past year.
Return vs Market: GENT exceeded the Norwegian Market which returned 8.5% over the past year.
Price Volatility
| GENT volatility | |
|---|---|
| GENT Average Weekly Movement | 8.1% |
| Medical Equipment Industry Average Movement | 5.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in NO Market | 10.9% |
| 10% least volatile stocks in NO Market | 2.6% |
Stable Share Price: GENT's share price has been volatile over the past 3 months.
Volatility Over Time: GENT's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Norwegian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 58 | Njaal Kind | www.gentian.com |
Gentian Diagnostics ASA researches, develops, and produces biochemical reagents for use in medical diagnostics and research worldwide. The company offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Circulating Calprotectin Immunoassay, a turbidimetric immunoassay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a glomerular filtration rate marker for the diagnosis and therapeutic control of renal function; Gentian Retinol-Binding Protein Immunoassay for detection of retinol-binding protein in human serum and plasma; and canine CRP immunoassay test kit, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine C-reactive protein in dog plasma and serum. It also provides SARS-CoV-2 total antibody immunoassay, quantitative antibody test captures the full immune response detecting antibodies targeting the S1-subunit.
Gentian Diagnostics ASA Fundamentals Summary
| GENT fundamental statistics | |
|---|---|
| Market cap | NOK 863.65m |
| Earnings (TTM) | -NOK 5.83m |
| Revenue (TTM) | NOK 149.41m |
5.8x
P/S Ratio-148.1x
P/E RatioIs GENT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GENT income statement (TTM) | |
|---|---|
| Revenue | NOK 149.41m |
| Cost of Revenue | NOK 68.88m |
| Gross Profit | NOK 80.53m |
| Other Expenses | NOK 86.37m |
| Earnings | -NOK 5.83m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 29, 2024
| Earnings per share (EPS) | -0.38 |
| Gross Margin | 53.90% |
| Net Profit Margin | -3.90% |
| Debt/Equity Ratio | 0% |
How did GENT perform over the long term?
See historical performance and comparison